BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 25160518)

  • 1. A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers.
    Zaltzman JS; Lai V; Schulz MZ; Moon KH; Cherney DZ
    Transpl Int; 2014 Dec; 27(12):1294-302. PubMed ID: 25160518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily cyclosporine on renal function in healthy volunteers.
    Zaltzman JS
    Transplantation; 2010 Dec; 90(11):1185-91. PubMed ID: 21166111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Inhibition of Calcineurin Activity With a Melt-Dose Once-daily Tacrolimus Formulation in Renal Transplant Recipients.
    Fontova P; Colom H; Rigo-Bonnin R; Bestard O; Vidal-Alabró A; van Merendonk LN; Cerezo G; Polo C; Montero N; Melilli E; Manonelles A; Meneghini M; Coloma A; Cruzado JM; Torras J; Grinyó JM; Lloberas N
    Clin Pharmacol Ther; 2021 Jul; 110(1):238-247. PubMed ID: 33626199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial.
    Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K;
    Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study.
    Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR
    Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant.
    DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR
    Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended release versus immediate release tacrolimus in kidney transplant recipients: a systematic review and meta-analysis.
    Saengram W; Vadcharavivad S; Poolsup N; Chancharoenthana W
    Eur J Clin Pharmacol; 2018 Oct; 74(10):1249-1260. PubMed ID: 29961086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial.
    Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K
    Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant Recipients.
    Allard M; Puszkiel A; Conti F; Chevillard L; Kamar N; Noé G; White-Koning M; Thomas-Schoemann A; Simon T; Vidal M; Calmus Y; Blanchet B
    Clin Ther; 2019 May; 41(5):882-896.e3. PubMed ID: 31003735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta Cell Function and Insulin Resistance After Conversion from Tacrolimus Twice-Daily to Extended-Release Tacrolimus Once-Daily in Stable Renal Transplant Recipients.
    Ruangkanchanasetr P; Sanohdontree N; Supaporn T; Sathavarodom N; Satirapoj B
    Ann Transplant; 2016 Dec; 21():765-774. PubMed ID: 27980321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study.
    Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L
    Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Switching From Immediate- or Prolonged-Release to Once-Daily Extended-Release Tacrolimus (LCPT) on Tremor in Stable Kidney Transplant Recipients: The Observational ELIT Study.
    Giral M; Grimbert P; Morin B; Bouvier N; Buchler M; Dantal J; Garrigue V; Bertrand D; Kamar N; Malvezzi P; Moreau K; Athea Y; Le Meur Y
    Transpl Int; 2024; 37():11571. PubMed ID: 38694490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation.
    Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L
    Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients.
    Stifft F; Undre N; van Hooff JP; Christiaans MH
    Ther Drug Monit; 2016 Aug; 38(4):456-62. PubMed ID: 27128604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late Conversion of Kidney Transplant Recipients from Ciclosporin to Tacrolimus Improves Graft Function: Results from a Randomized Controlled Trial.
    Plischke M; Riegersperger M; Dunkler D; Heinze G; Kikić Ž; Winkelmayer WC; Sunder-Plassmann G
    PLoS One; 2015; 10(8):e0135674. PubMed ID: 26270340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.